In order to remain compliant with the NASDAQ listing rules, it could be that ATH (ATHE on NASDAQ) may do a reverse stock spilt soon which would have to be at least a 1:2 or more likely a 1:5 or 1:10. This would probably see a further devaluing in the stock price and market cap, given that no significant news due probably for at least a year. ATH do not seem interested in promoting any positive news with PBT2 and are basically a one product company and this is after 22 years of being listed on the ASX. An appalling record, given that their aim from the start was to commercialise research into neurodegenerative diseases. All that they have got to show at the moment is a share price languishing at an all time low.
ATH Price at posting:
1.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)